Laurie Letvak

Vice President and Head of Clinical Development Policy Dr. Laurie Letvak is Vice President and Head of Clinical Development Policy at Novartis, a position she has held since June 2014. Laurie has been with Novartis for 20 years in a variety of positions.  She played a key role in the development of Gleevec® since joining the International Project Team in 2001, responsible for Global Medical Affairs.   She led the development of the Medical Affairs program, which resulted in many key studies, some of which have provided the data for new indications for Gleevec ®, including Ph+ ALL and Adjuvant GIST.   From 2008-2012, she had been the Global Program Head for Glivec and Tasigna within Oncology Global Development at Novartis.  In this role was responsible for leading the global development efforts for both drugs, including registration programs for new indications.  Laurie assumed the position of Global Development Head for the  Critical Care Franchise  February, 2012.  In that role she was responsible for co-leading this worldwide franchise in partnership with the commercial head and in particular was responsible for the strategic development and execution of plans for development of the evolving portfolio, which focuses on specialty cardiovascular (with emphasis on heart failure) and metabolic products, particularly for lipids and atherosclerosis. Laurie  received her undergraduate and medical degrees from Cornell University.  She did her internal medicine trainin...
Source: PHRMA - Category: Pharmaceuticals Authors: Source Type: news